242 related articles for article (PubMed ID: 29843069)
1. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
Wang M; Liang L; Lei X; Multani A; Meric-Bernstam F; Tripathy D; Wu Y; Chen H; Zhang H
Ann Diagn Pathol; 2018 Aug; 35():69-76. PubMed ID: 29843069
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
[TBL] [Abstract][Full Text] [Related]
3. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
Catenacci DV; Ang A; Liao WL; Shen J; O'Day E; Loberg RD; Cecchi F; Hembrough T; Ruzzo A; Graziano F
Cancer; 2017 May; 123(6):1061-1070. PubMed ID: 27926778
[TBL] [Abstract][Full Text] [Related]
4. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
5. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of HER2 status in breast carcinoma using fully automated HER2 staining and fluorescence in-situ hybridization technology].
Ying JM; Liu XY; Guo L; Xie YQ; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):296-300. PubMed ID: 22883666
[TBL] [Abstract][Full Text] [Related]
7. Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.
Preusser M; Streubel B; Berghoff AS; Hainfellner JA; von Deimling A; Widhalm G; Dieckmann K; Wöhrer A; Hackl M; Zielinski C; Birner P
Histopathology; 2014 Nov; 65(5):684-92. PubMed ID: 25039982
[TBL] [Abstract][Full Text] [Related]
8. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
[TBL] [Abstract][Full Text] [Related]
9. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
Park S; Choi YL; Sung CO; An J; Seo J; Ahn MJ; Ahn JS; Park K; Shin YK; Erkin OC; Song K; Kim J; Shim YM; Han J
Histol Histopathol; 2012 Feb; 27(2):197-207. PubMed ID: 22207554
[TBL] [Abstract][Full Text] [Related]
10. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
[TBL] [Abstract][Full Text] [Related]
11. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
12. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
13. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
14. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system.
Ciampa A; Xu B; Ayata G; Baiyee D; Wallace J; Wertheimer M; Edmiston K; Khan A
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):132-7. PubMed ID: 16785779
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor overexpression/amplification in adenocarcinomas arising in the gastrointestinal tract.
Rossi E; Villanacci V; Danesino C; Donato F; Nascimbeni R; Bassotti G
Rev Esp Enferm Dig; 2011 Dec; 103(12):632-9. PubMed ID: 22217347
[TBL] [Abstract][Full Text] [Related]
16. MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non-Small-cell Lung Cancer.
Yin W; Cheng J; Tang Z; Toruner G; Hu S; Guo M; Robinson M; Medeiros LJ; Tang G
Clin Lung Cancer; 2021 Jul; 22(4):e512-e518. PubMed ID: 33288441
[TBL] [Abstract][Full Text] [Related]
17. Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer.
Nakajima H; Ishikawa Y; Furuya M; Sano T; Ohno Y; Horiguchi J; Oyama T
Breast Cancer; 2014 Jan; 21(1):66-74. PubMed ID: 22481575
[TBL] [Abstract][Full Text] [Related]
18. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
[TBL] [Abstract][Full Text] [Related]
19. [HER-2 overexpression and gene amplification of advanced breast cancers determined by fluorescence in situ hybridization in fine needle aspiration specimens].
Zhang Z; Zhao L; Guo H; Guo L; Ling Y; Xu X; Zhao H; Pan Q
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):183-7. PubMed ID: 24785277
[TBL] [Abstract][Full Text] [Related]
20. MET amplification, protein expression, and mutations in pulmonary adenocarcinoma.
Park S; Koh J; Kim DW; Kim M; Keam B; Kim TM; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2015 Dec; 90(3):381-7. PubMed ID: 26791796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]